Clinical Cancer Research, Vol 2, Issue 8 1369-1372, Copyright © 1996 by American Association for Cancer Research

ARTICLES

TIMP1 and adverse prognosis in non-small cell lung cancer

KM Fong, Y Kida, PV Zimmerman and PJ Smith
Queensland Cancer Fund Research Unit, Department of Pathology, University of Queensland Medical School, Herston, Queensland 4006, Australia.

The tumor inhibitor of metalloproteinase (TIMP) family is a natural inhibitor of several matrix metalloproteinase enzymes which are involved in the process of tumor cell invasion through the extracellular matrix. The aim of this study was to examine TIMP1 RNA expression levels in relation to the clinicopathological features in resected primary non-small cell lung cancer (NSCLC). Total cellular RNA, obtained from 45 cases of NSCLC and adjacent normal lung tissue, was examined using Northern blot analysis. TIMP1 RNA expression levels were heterogeneous in NSCLC but was significantly higher in the adenocarcinoma compared to the squamous cell carcinoma subtype. Although the TIMP1 RNA levels did not correlate with sex, smoking, tumor, node, or TNM stage, there was a statistically significant survival disadvantage for cases with relatively high TIMP1 RNA expression, suggesting a role for TIMP1 in determining the prognosis of resected NSCLC.

This article has been cited by other articles:

				C.-S. Wang, T.-L. Wu, K.-C. Tsao, and C.-F. Sun Serum TIMP-1 in Gastric Cancer Patients: A Potential Prognostic Biomarker. Ann. Clin. Lab. Sci., December 1, 2006; 36(1): 23 - 30. [Abstract] [Full Text] [PDF]

				I. V. Sorensen, C. Fenger, H. Winther, N. T. Foged, U. Lademann, N. Brunner, and P. A. Usher Characterization of Anti-TIMP-1 Monoclonal Antibodies for Immunohistochemical Localization in Formalin-fixed, Paraffin-embedded Tissue J. Histochem. Cytochem., October 1, 2006; 54(10): 1075 - 1086. [Abstract] [Full Text] [PDF]

				M. Yamazaki, T. Akahane, T. Buck, H. Yoshiji, D. E. Gomez, D. J. Schoeffner, E. Okajima, S. R. Harris, O. R. Bunce, S. S. Thorgeirsson, et al. Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice Carcinogenesis, September 1, 2004; 25(9): 1735 - 1746. [Abstract] [Full Text] [PDF]

				I. S. Aljada, N. Ramnath, K. Donohue, S. Harvey, J. J. Brooks, S. M. Wiseman, T. Khoury, G. Loewen, H. K. Slocum, T. M. Anderson, et al. Upregulation of the Tissue Inhibitor of Metalloproteinase-1 Protein Is Associated With Progression of Human Non-Small-Cell Lung Cancer J. Clin. Oncol., August 15, 2004; 22(16): 3218 - 3229. [Abstract] [Full Text] [PDF]

				G. C. Durkan, J. E. Nutt, C. Marsh, P. H. Rajjayabun, M. C. Robinson, D. E. Neal, J. Lunec, and J. K. Mellon Alteration in Urinary Matrix Metalloproteinase-9 to Tissue Inhibitor of Metalloproteinase-1 Ratio Predicts Recurrence in Nonmuscle-invasive Bladder Cancer Clin. Cancer Res., July 1, 2003; 9(7): 2576 - 2582. [Abstract] [Full Text] [PDF]

				M. N. Holten-Andersen, I. J. Christensen, H. J. Nielsen, H. Lilja, G. Murphy, V. Jensen, N. Brunner, and T. Piironen Measurement of the Noncomplexed Free Fraction of Tissue Inhibitor of Metalloproteinases 1 in Plasma by Immunoassay Clin. Chem., August 1, 2002; 48(8): 1305 - 1313. [Abstract] [Full Text] [PDF]

				G. C. Durkan, J. E. Nutt, P. H. Rajjayabun, D. E. Neal, J. Lunec, and J. K. Mellon Prognostic Significance of Matrix Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinase-1 in Voided Urine Samples from Patients with Transitional Cell Carcinoma of the Bladder Clin. Cancer Res., November 1, 2001; 7(11): 3450 - 3456. [Abstract] [Full Text] [PDF]

				B. V. S. Kallakury, S. Karikehalli, A. Haholu, C. E. Sheehan, N. Azumi, and J. S. Ross Increased Expression of Matrix Metalloproteinases 2 and 9 and Tissue Inhibitors of Metalloproteinases 1 and 2 Correlate with Poor Prognostic Variables in Renal Cell Carcinoma Clin. Cancer Res., October 1, 2001; 7(10): 3113 - 3119. [Abstract] [Full Text] [PDF]

				S. Ylisirnio, M. Hoyhtya, R. Makitaro, P. Paaakko, J. Risteli, V. L. Kinnula, T. Turpeenniemi-Hujanen, and A. Jukkola Elevated Serum Levels of Type I Collagen Degradation Marker ICTP and Tissue Inhibitor of Metalloproteinase (TIMP) 1 Are Associated with Poor Prognosis in Lung Cancer Clin. Cancer Res., June 1, 2001; 7(6): 1633 - 1637. [Abstract] [Full Text] [PDF]

				Y. Jiang, M. Wang, M. Y. Çeliker, Y. E. Liu, Q. X. Amy Sang, I. D. Goldberg, and Y. E. Shi Stimulation of Mammary Tumorigenesis by Systemic Tissue Inhibitor of Matrix Metalloproteinase 4 Gene Delivery Cancer Res., March 1, 2001; 61(6): 2365 - 2370. [Abstract] [Full Text]

				M. Hidalgo and S. G. Eckhardt Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy J Natl Cancer Inst, February 7, 2001; 93(3): 178 - 193. [Abstract] [Full Text] [PDF]

				M. N. Holten-Andersen, R. W. Stephens, H. J. Nielsen, G. Murphy, I. J. Christensen, W. Stetler-Stevenson, and N. Brunner High Preoperative Plasma Tissue Inhibitor of Metalloproteinase-1 Levels Are Associated with Short Survival of Patients with Colorectal Cancer Clin. Cancer Res., November 1, 2000; 6(11): 4292 - 4299. [Abstract] [Full Text] [PDF]

				G. Li, R. Fridman, and H.-R. C. Kim Tissue Inhibitor of Metalloproteinase-1 Inhibits Apoptosis of Human Breast Epithelial Cells Cancer Res., December 1, 1999; 59(24): 6267 - 6275. [Abstract] [Full Text] [PDF]

				M. Michael, B. Babic, R. Khokha, M. Tsao, J. Ho, M. Pintilie, K. Leco, D. Chamberlain, and F. A. Shepherd Expression and Prognostic Significance of Metalloproteinases and Their Tissue Inhibitors in Patients With Small-Cell Lung Cancer J. Clin. Oncol., June 1, 1999; 17(6): 1802 - 1802. [Abstract] [Full Text] [PDF]

				A. Price, Q. Shi, D. Morris, M. E. Wilcox, P. M. A. Brasher, N. B. Rewcastle, D. Shalinsky, H. Zou, K. Appelt, R. N. Johnston, et al. Marked Inhibition of Tumor Growth in a Malignant Glioma Tumor Model by a Novel Synthetic Matrix MetalloproteinaseInhibitor AG3340 Clin. Cancer Res., April 1, 1999; 5(4): 845 - 854. [Abstract] [Full Text] [PDF]

				G Cox, W P Steward, and K J O'Byrne The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer Thorax, February 1, 1999; 54(2): 169 - 179. [Full Text]